Quantcast

Latest XBiotech Stories

2014-06-23 12:29:04

AUSTIN, Texas, June 23, 2014 /PRNewswire/ -- XBiotech announced today that Gary Gonzales has joined the Company as Vice President of Clinical Operations. Mr. Gonzales will lead XBiotech's clinical trial team and manage the Company's international clinical operations. Mr. Gonzales joins XBiotech from INC Research where he managed large, global pivotal phase III trials. Mr. Gonzales has B.S. & M.S. degrees in chemistry and biology and also holds a M.B.A. Mr. Gonzales comes to...

2014-04-15 16:27:51

AUSTIN, Texas, April 15, 2014 /PRNewswire/ -- XBiotech announced today that Robert Lindsey has joined the Company as Senior Vice President Corporate Development & General Counsel. Mr. Lindsey joins XBiotech from Dell where he served as Legal Director. In that capacity, Mr. Lindsey acted as the sole securities counsel for Dell and was the primary attorney responsible for the treasury, accounting, investor relations, corporate communications and internal audit groups. Most recently,...

2014-04-03 16:23:53

AUSTIN, Texas, April 3, 2014 /PRNewswire/ -- XBiotech announced today that it acquired the patent estate of Strox Biopharmaceuticals relating to antibody therapies for methicillin resistant staphylococcus aureus (MRSA). XBiotech is developing next generation natural immune therapies to address serious and drug resistant bacterial infections. The in-licensed technology is reportedly intended to expand and strengthen XBiotech's position for its infectious disease product development...

2014-03-11 16:25:50

AUSTIN, Texas, March 11, 2014 /PRNewswire/ -- XBiotech announced today that the United States Patent and Trademark Office (USPTO) granted another key patent to support the Company's growing portfolio around its lead product candidate. The new patent grants XBiotech exclusive rights to target a unique molecule associated with chronic sterile inflammation. The patent relates to antibodies and methods of using these antibodies to treat, prevent, and detect disease progression associated...

2014-01-16 16:24:09

AUSTIN, Texas, Jan. 16, 2014 /PRNewswire/ -- XBiotech announced today that it has launched a Phase II study to treat a rare but debilitating disorder, Pyoderma Gangrenosum (PG). This study is based on efficacy seen with anti-IL-1 therapeutic antibody in previous dermatological clinical studies such as psoriasis and acne. PG is expected to be considered an "orphan indication" by the FDA, facilitating expedited clinical development to market. Dr. Armand Cognetta, lead clinical...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related